Skip to main content
Premium Trial:

Request an Annual Quote

C2i Genomics Expands to India via Karkinos Healthcare Partnership

NEW YORK – C2i Genomics has entered the cancer detection and management market in India by virtue of a strategic partnership, announced last week, with Karkinos Healthcare, an Indian developer of a cancer-management technology platform.

Through the partnership, New York-based C2i Genomics will bring its C2inform whole-genome sequencing minimal residual disease (MRD) test to India, expanding on the MRD monitoring Karkinos already offers in its home country.

The C2inform assay uses patient-specific discriminators developed via artificial intelligence-based pattern recognition and error suppression methods that integrates signals for highly sensitive detection of tumor-associated DNA. C2i received a CE mark to launch the product in Europe earlier this year.

Karkinos will launch C2inform at its Advanced Center for Cancer Diagnostics and Research at Kochi, India. Because analysis is performed in the cloud, C2i's software platform can monitor cancer tumor burden from anywhere in the world, the company said.

"Karkinos Healthcare shares in our vision to increase access to distributed cancer monitoring and will be instrumental in advancing our commercialization efforts to bring the C2inform MRD test to labs across India," C2i CEO and Cofounder Asaf Zviran said in a statement.

C2i has formed strategic partnerships for AI-based cancer detection and monitoring across the Western world, including one announced this year with OncoDNA.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.